title: Seizure prophylaxis in patients with brain tumors: a meta-analysis.
abstract: OBJECTIVE
  To assess whether antiepileptic drugs (AEDs) should be prescribed to patients with brain tumors who have no history of seizures.
  
  
  METHODS
  We performed a meta-analysis of randomized controlled trials (1966-2004) that evaluated the efficacy of AED prophylaxis vs no treatment or placebo to prevent seizures in patients with brain tumors who had no history of epilepsy. Summary odds ratios (ORs) were calculated using a random-effects model. Three subanalyses were performed to assess pooled ORs of seizures in patients with primary glial tumors, cerebral metastases, and meningiomas.
  
  
  RESULTS
  Of 474 articles found in the initial search, 17 were identified as primary studies. Five trials met inclusion criteria: patients with a neoplasm (primary glial tumors, cerebral metastases, and meningiomas) but no history of epilepsy who were randomized to either an AED or placebo. The 3 AEDs studied were phenobarbital, phenytoin, and valproic acid. Of the 5 trials, 4 showed no statistical benefit of seizure prophylaxis with an AED. Meta-analysis confirmed the lack of AED benefit at 1 week (OR, 0.91; 95% confidence interval [CI], 0.45-1.83) and at 6 months (OR, 1.01; 95% CI, 0.51-1.98) of follow-up. The AEDs had no effect on seizure prevention for specific tumor pathology, including primary glial tumors (OR, 3.46; 95% CI, 0.32-37.47), cerebral metastases (OR, 2.50; 95% CI, 0.25-24.72), and meningiomas (OR, 0.62; 95% CI, 0.10-3.85).
  
  
  CONCLUSIONS
  No evidence supports AED prophylaxis with phenobarbital, phenytoin, or valproic acid in patients with brain tumors and no history of seizures, regardless of neoplastic type. Subspecialists who treat patients with brain tumors need more education on this issue. Future randomized controlled trials should address whether any of the newer AEDs are useful for seizure prophylaxis.
authors.affiliation: Department of Neurology Mayo Clinic College of Medicine, Scottsdale, Ariz, USA. sirven.joseph@mayo.edu
authors.forename: Joseph I
authors.initials: JI
authors.lastname: Sirven
authors.forename: Dean M
authors.initials: DM
authors.lastname: Wingerchuk
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Drazkowski
authors.forename: Mark K
authors.initials: MK
authors.lastname: Lyons
authors.forename: Richard S
authors.initials: RS
authors.lastname: Zimmerman
mesh_terms: D000927:Anticonvulsants / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000453:epidemiology*; D015897:Comorbidity; D016001:Confidence Intervals; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D016017:Odds Ratio; D010634:Phenobarbital / Q000008:administration & dosage; D010672:Phenytoin / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012640:Seizures / Q000453:epidemiology* / Q000517:prevention & control*; D017211:Treatment Failure; D014635:Valproic Acid / Q000008:administration & dosage
chemical_list: D000927:Anticonvulsants; D014635:Valproic Acid; D010672:Phenytoin; D010634:Phenobarbital